FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038701282> ?p ?o ?g. }

• W2038701282 endingPage "65" @default.
• W2038701282 startingPage "60" @default.
• W2038701282 abstract "background: Philadelphia-Chromosome-positive (Ph-positive) acute lymphocytic leukemia (ALL) is associated with poor outcome in children as well as in adults. We report our experience in patients with Ph-positive ALL and review their clinico-laboratory characteristics, response to different therapies, and overall prognosis. patients and methods: Since 1980, 41 newly diagnosed patients with Ph-positive ALL were referred to our service. In addition to confirmation of their diagnosis by morphologic studies of bone marrow aspiration and biopsy specimens, patients underwent cytogenetic, immunophenotypic, and molecular studies. Thirty-five patients received vincristine-Adriamycin-dexamethasone (VAD) or cyclophosphamide (CVAD) induction regimens, and 6 patients were treated with other combinations. Thirty-seven patients received salvage therapy that included VAD, high-dose cytosine arabinoside (ara-C)-containing regimens, methotrexate-asparaginase, and high-dose chemotherapy with autologous or allogeneic bone marrow transplantation (BMT). results: The 41 patients were among 334 patients with ALL (12%) seen during that same period. Patients with Ph-positive ALL were older and had a significantly lower incidence of anemia and a higher incidence of peripheral leukocytosis, FAB L2 (Fench-American-British) morphology, common acute lymphocytic leukemia antigens (CALLA), and CD34 marker positivity. With induction chemotherapy, 23 of 41 Ph-positive ALL patients (56%) achieved complete remission, and their median survival and remission duration were 11 months and 9 months, respectively. Thirteen of 31 Ph-positive ALL patients (42%) achieved complete response with high-dose ara-C regimens during salvage therapy. conclusions: In our experience, patients with Ph-positive ALL are usually older, have FAB L2 morphology, and are CALLA-positive and CD34-positive. These patients have a poor prognosis when treated with conventional approaches with lower overall complete response rate, shorter remission duration, and shorter survival. There appears to be a selective sensitivity to high-dose ara-C in these patients that suggests a possible role of this agent as part of early consolidation or induction regimens." @default.
• W2038701282 created "2016-06-24" @default.
• W2038701282 creator A5006104041 @default.
• W2038701282 creator A5030171128 @default.
• W2038701282 creator A5030500582 @default.
• W2038701282 creator A5061835464 @default.
• W2038701282 creator A5070096873 @default.
• W2038701282 creator A5090435894 @default.
• W2038701282 date "1994-07-01" @default.
• W2038701282 modified "2023-10-12" @default.
• W2038701282 title "Philadelphia-chromosome-positive adult acute lymphocytic leukemia: Characteristics, treatment results, and prognosis in 41 patients" @default.
• W2038701282 cites W175560591 @default.
• W2038701282 cites W1834314364 @default.
• W2038701282 cites W1977312224 @default.
• W2038701282 cites W1980949053 @default.
• W2038701282 cites W2012891007 @default.
• W2038701282 cites W2018248988 @default.
• W2038701282 cites W2033204947 @default.
• W2038701282 cites W2040323778 @default.
• W2038701282 cites W2053310263 @default.
• W2038701282 cites W2053906221 @default.
• W2038701282 cites W2057375535 @default.
• W2038701282 cites W2158824654 @default.
• W2038701282 cites W2180813806 @default.
• W2038701282 cites W2220697339 @default.
• W2038701282 cites W2231278437 @default.
• W2038701282 cites W2254222484 @default.
• W2038701282 cites W2339475636 @default.
• W2038701282 cites W2412039589 @default.
• W2038701282 cites W2419612161 @default.
• W2038701282 cites W4293241248 @default.
• W2038701282 doi "https://doi.org/10.1016/0002-9343(94)90049-3" @default.
• W2038701282 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8030658" @default.
• W2038701282 hasPublicationYear "1994" @default.
• W2038701282 type Work @default.
• W2038701282 sameAs 2038701282 @default.
• W2038701282 citedByCount "122" @default.
• W2038701282 countsByYear W20387012822012 @default.
• W2038701282 countsByYear W20387012822013 @default.
• W2038701282 countsByYear W20387012822014 @default.
• W2038701282 countsByYear W20387012822015 @default.
• W2038701282 countsByYear W20387012822016 @default.
• W2038701282 countsByYear W20387012822017 @default.
• W2038701282 countsByYear W20387012822019 @default.
• W2038701282 countsByYear W20387012822020 @default.
• W2038701282 countsByYear W20387012822021 @default.
• W2038701282 crossrefType "journal-article" @default.
• W2038701282 hasAuthorship W2038701282A5006104041 @default.
• W2038701282 hasAuthorship W2038701282A5030171128 @default.
• W2038701282 hasAuthorship W2038701282A5030500582 @default.
• W2038701282 hasAuthorship W2038701282A5061835464 @default.
• W2038701282 hasAuthorship W2038701282A5070096873 @default.
• W2038701282 hasAuthorship W2038701282A5090435894 @default.
• W2038701282 hasConcept C104317684 @default.
• W2038701282 hasConcept C120665830 @default.
• W2038701282 hasConcept C121332964 @default.
• W2038701282 hasConcept C126322002 @default.
• W2038701282 hasConcept C138626823 @default.
• W2038701282 hasConcept C141071460 @default.
• W2038701282 hasConcept C185592680 @default.
• W2038701282 hasConcept C2776694085 @default.
• W2038701282 hasConcept C2776755627 @default.
• W2038701282 hasConcept C2778461978 @default.
• W2038701282 hasConcept C2778904597 @default.
• W2038701282 hasConcept C2779263901 @default.
• W2038701282 hasConcept C2779429289 @default.
• W2038701282 hasConcept C2780007613 @default.
• W2038701282 hasConcept C2781107101 @default.
• W2038701282 hasConcept C2909962599 @default.
• W2038701282 hasConcept C55493867 @default.
• W2038701282 hasConcept C61511704 @default.
• W2038701282 hasConcept C71924100 @default.
• W2038701282 hasConcept C90924648 @default.
• W2038701282 hasConceptScore W2038701282C104317684 @default.
• W2038701282 hasConceptScore W2038701282C120665830 @default.
• W2038701282 hasConceptScore W2038701282C121332964 @default.
• W2038701282 hasConceptScore W2038701282C126322002 @default.
• W2038701282 hasConceptScore W2038701282C138626823 @default.
• W2038701282 hasConceptScore W2038701282C141071460 @default.
• W2038701282 hasConceptScore W2038701282C185592680 @default.
• W2038701282 hasConceptScore W2038701282C2776694085 @default.
• W2038701282 hasConceptScore W2038701282C2776755627 @default.
• W2038701282 hasConceptScore W2038701282C2778461978 @default.
• W2038701282 hasConceptScore W2038701282C2778904597 @default.
• W2038701282 hasConceptScore W2038701282C2779263901 @default.
• W2038701282 hasConceptScore W2038701282C2779429289 @default.
• W2038701282 hasConceptScore W2038701282C2780007613 @default.
• W2038701282 hasConceptScore W2038701282C2781107101 @default.
• W2038701282 hasConceptScore W2038701282C2909962599 @default.
• W2038701282 hasConceptScore W2038701282C55493867 @default.
• W2038701282 hasConceptScore W2038701282C61511704 @default.
• W2038701282 hasConceptScore W2038701282C71924100 @default.
• W2038701282 hasConceptScore W2038701282C90924648 @default.
• W2038701282 hasIssue "1" @default.
• W2038701282 hasLocation W20387012821 @default.
• W2038701282 hasLocation W20387012822 @default.
• W2038701282 hasOpenAccess W2038701282 @default.
• W2038701282 hasPrimaryLocation W20387012821 @default.

• next